France hits Roche and Novartis with €444 million fine
France’s Competition Authority has fined Roche, Novartis and Genentech a total of €444 million for abusing their collective dominance by preventing the entry of a cheaper eye treatment drug into the French market.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.